Prion Disease is a rare, progressive, and fatal neurodegenerative disorder caused by the accumulation of a misfolded prion protein in the brain. Prion diseases, also known as transmissible spongiform encephalopathies, affect both humans and animals. In humans, the most common forms are Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker Syndrome (GSS), familial fatal insomnia (FFI), and kuru. Prion diseases are caused by misfolded proteins that become detectable in the form of aggregates or amyloid deposits in the brain. Prion proteins are primarily composed of amino acids. These proteins, when present in a normal configuration, are essential for normal cell functions. However, in the presence of the misfolded form, the prion proteins cause an infection that leads to misfolding of the normal protein in cells, which is then passed between cells when they come into contact. The misfolded structure of the prion protein causes the cell to accumulate the abnormal protein and leads to neuronal death and other degenerative changes. Due to its infectious nature and the fact that the misfolded proteins are very resistant to degradation, prion diseases pose a significant public health threat. As the cause of prion diseases is still not fully understood, the treatment options tend to be limited to supportive care. The primary approach towards preventing the spread of prion diseases is to ensure that any contaminated food sources and medical equipment are properly disposed of, and that public health measures are in place to alert people to potential risks. Being diagnosed with prion diseases can be devastating, as the diseases typically have a rapid and fatal course. There currently is no cure, and at present, the prognosis tends to be grim. Research is ongoing in the area of prion diseases, with a focus on identifying potential treatments and possible ways to diagnose and monitor the progression of the disease in individuals.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom